Westlake Village, CA, US
Cynvenio Biosystems, Inc. is a molecular diagnostics company dedicated to the early detection and targeted treatment of cancer. Cynvenio has developed and deployed the LiquidBiopsy system to enable realtime monitoring of tumor cell-associated mutations from a simple blood draw. This information can be used by physicians, academic centers, and drug developers to define treatment cycles for individual patients, efficiently select patients for drug trials and monitor patient response at any stage of disease.
Cynvenios CLIA service lab is based in Westlake Village, California. To find out more about the company please visit: www.cynvenio.com and www.liquidbiopsy.com.
Chief Executive Officer
Fred Gluck is a former managing partner (chief executive) of McKinsey & Company, Inc.
After retiring from McKinsey in 1995, he joined the Bechtel Group, where he served as vice chairman and director.
He later rejoined McKinsey & Company as a consultant until retiring again in July 2003.
Mr. Gluck was the founding chairman and CEO of both CytomX and Cynvenio Biosystems and continues to serve as chairman of Cynvenio.
He also serves as director of a number of eleemosynary organizations, including the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus).
He recently retired form the Board of Amgen and was the presiding director of HCA (Hospital Corporation of America).
Mr. Gluck received his B.S. from Manhattan College and an M.S. from New York University: both degrees in electrical engineering.
Amit Munshi is currently the CEO of EPIRUS (formerly Fourteen22), an institutionally-backed company focused on the development of biosimilars globally. Previously the President and CEO of Percivia LLC, a Royal DSM / Crucell joint venture developing biosimilar molecules for emerging markets.
Prior to Percivia, Munshi was a co-founder and Chief Business Officer of Kythera Biopharmaceuticals Inc. (www.kytherabiopharma.com; NASDAQ: KYTH), a company focused on novel prescription therapeutics in the field of aesthetic medicine.
Mr. Munshi spent 8 years at Amgen Inc. Mr. Munshi's positions at Amgen included, General Manager of Amgens +$500M European Nephrology Business based in Switzerland, responsibility for Amgens inflammation marketing, and responsibility for global new product planning.
Munshi has previously also held positions in sales, market research, marketing, managed care, and product licensing during tenures at Astra Merck and IOLAB Corporation (a J&J Company).
|Prior Year Revenue
||Current Year Revenue
||Next Year Revenue
|Sign up as Investor
||Sign up as Investor
||Sign up as Investor
|11 years, 4 months
|Â© Copyright iCrowdNewswire LLC 2017.
Are you a nurse looking for a job?
Check out the Nursing Job Source.
Your number one choice for nursing jobs.